Suppr超能文献

韧带样瘤的当前观点

Current ideas in desmoid tumours.

作者信息

Sturt N Julian H, Clark Susan K

机构信息

Polyposis Registry, Cancer Research UK Colorectal Cancer Unit, St Mark's Hospital, HA1 3UJ, Harrow, UK.

出版信息

Fam Cancer. 2006;5(3):275-85; discussion 287-8. doi: 10.1007/s10689-005-5675-1.

Abstract

Desmoid tumours are rare neoplasms of fibroblastic origin which arise with disproportionate frequency in patients with familial adenomatous polyposis (FAP). They are thought to develop in about 10-25% of FAP patients and may be the leading cause of death amongst those who have undergone colectomy. Risk factors include trauma, having a distal germline APC mutation, having a family history of desmoids, and probably oestrogens. In very high-risk individuals there may be a case for delay of colectomy or chemoprophylaxis at the time of surgery. Desmoids are now known to be true neoplasms but with normal telomere length and telomerase activity. FAP-associated tumours seem to carry biallelic APC mutations, one of which lies in the distal part of the gene. Such loss of wild-type APC seems to occur relatively late in tumour development. It is likely that beta-catenin plays an important role in tumourigenesis. FAP-associated desmoids tend to arise in the abdomen or abdominal wall. CT scanning gives the best information on tumour anatomy whilst T2-weighted MRI indicates likely behaviour. Treatment may simply consist of observation. Otherwise, usual first-line therapy is with sulindac with or without an anti-oestrogen. Cytotoxic chemotherapy is an option in unresectable tumours. Surgery is a reasonable first-line treatment in abdominal wall tumours but is risky for intra-abdominal tumours and may necessitate massive small bowel resection. Desmoids are the greatest remaining challenge in the management of FAP and further research into their aetiology needs to be combined with multicentre clinical trials of new treatments in order to improve management of the disease.

摘要

硬纤维瘤是一种罕见的成纤维细胞源性肿瘤,在家族性腺瘤性息肉病(FAP)患者中出现的频率不成比例地高。据认为,约10%-25%的FAP患者会发生硬纤维瘤,它可能是接受结肠切除术后患者的主要死亡原因。危险因素包括创伤、携带远端种系APC突变、有硬纤维瘤家族史,可能还有雌激素。在极高风险个体中,可能有理由推迟结肠切除术或在手术时进行化学预防。现在已知硬纤维瘤是真正的肿瘤,但端粒长度和端粒酶活性正常。FAP相关肿瘤似乎携带双等位基因APC突变,其中一个位于该基因的远端部分。野生型APC的这种缺失似乎在肿瘤发展过程中相对较晚发生。β-连环蛋白可能在肿瘤发生中起重要作用。FAP相关的硬纤维瘤往往发生在腹部或腹壁。CT扫描能提供关于肿瘤解剖结构的最佳信息,而T2加权MRI则可显示其可能的行为。治疗可能仅包括观察。否则,通常的一线治疗是使用舒林酸,可加用或不加用抗雌激素药物。细胞毒性化疗是不可切除肿瘤的一种选择。手术是腹壁肿瘤合理的一线治疗方法,但对腹腔内肿瘤有风险,可能需要进行大量小肠切除。硬纤维瘤是FAP管理中最大的遗留挑战,对其病因的进一步研究需要与新治疗方法的多中心临床试验相结合,以改善该疾病的管理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验